DCM
ARQT icon

Davis Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Davis Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$159 Buy
+6
New +$157 ﹤0.01% 918

Other funds holding ARQT

TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

Davis Capital Management's ARQT Position: Q3 2026 in Review

Davis Capital Management opened a new position in Arcutis Biotherapeutics (ARQT) in Q3 2026: 6 shares worth $159. The stake represents ﹤0.01% of the portfolio and ranks #918 among its holdings.

7 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Davis Capital Management held 6 shares of Arcutis Biotherapeutics worth $159 as of Q3 2026.
  • Arcutis Biotherapeutics was a new Davis Capital Management position in Q3 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #918 holding.
  • 7 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.